February brought policy updates and several biosimilar approvals, including the first FDA approval for an insulin aspart ...
Patients with non-small cell lung cancer (NSCLC) taking bevacizumab biosimilars demonstrated equivalent therapeutic efficacy ...
On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy ...
Number 4: Celltrion expands its reach in Europe, securing marketing authorization from the European Commission (EC) for its denosumab biosimilar candidate (Stoboclo and Osenvelt) and its aflibercept ...
The FDA and European Medicines Agency (EMA) mandate high similarity between biosimilars and reference products, but their ...
Three ustekinumab biosimilars enter the US market, expanding access to more affordable options referencing Stelara ...
Travis Brewer, vice president of payer and public health strategy at Texas Oncology, discusses the role of biosimilars in ...
Celltrion expands its reach in Europe, securing marketing authorization from the European Commission (EC) for its denosumab ...
The FDA and European Medicines Agency (EMA) granted approval, with interchangeability in the US, to Samsung Bioepis' ...
Number 5: The FDA approved Merilog (insulin-aspart-szjj) as the first biosimilar to reference Novolog (insulin aspart) for the treatment of adult and pediatric patients with type 2 diabetes. Number 4: ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback